Novavax (Rockville, MD) recently achieved positive Phase 2a results for its trivalent virus-like particle (VLP) vaccine against seasonal influenza, and positive preclinical results for a VLP vaccine against H1NI (swine) flu.
Novavax (Rockville, MD) recently achieved positive Phase 2a results for its trivalent virus-like particle (VLP) vaccine against seasonal influenza, and positive preclinical results for a VLP vaccine against H1NI (swine) flu.
In the Phase 2 trial for seasonal flu, the VLP vaccine induced strong hemagglutination inhibition (HAI) antibody responses against the influenza H1N1, H3N2, and B strains. Robust HAI responses were also observed against drifted H3N2 strains, showing the potential for VLP vaccines to be cross-protective against flu viruses from different seasons without the addition of an adjuvant. The vaccine was also well tolerated and no serious adverse events were reported.
The preclinical study for H1N1 in ferrets was conducted jointly by Novavax and the Centers for Disease Control and Prevention (Atlanta, GA). All of the H1N1 vaccinated animals, including those in the lowest (3.75 mcg) dose group, developed hemagglutination inhibition (HI) antibody titers of 1:40 or higher, considered a protective level of immunity, against the H1N1 virus.
Novavax produced the candidate H1NI vaccine and delivered it to the CDC in less than four weeks from the day the genetic sequences of the virus strain became available. The speed at which a vaccine can be produced is one of the main advantages of the VLP technology.
Previous coverage:
Small Vaccine Company Ready to Play its Part in Response to H1N1 Influenza
May 4, 2009
An Alternative to the Scale-up and Distribution of Pandemic Influenza Vaccine
Jan 2, 2009
James M. Robinson
Novavax Licenses VLP Vaccine Technology to Spanish Company ROVI
July 9, 2009
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.